| Literature DB >> 21109304 |
Samantha L Price1, Jeffrey E Lancet, Timothy J George, Gene A Wetzstein, Alan F List, Viet Q Ho, Hugo F Fernandez, Javier Pinilla-Ibarz, Mohamed A Kharfan-Dabaja, Rami S Komrokji.
Abstract
There is no standard salvage regimen for AML. We retrospectively compared two commonly used regimens at our institution: CLAG and MEC. The complete response rate (CR) was 37.9% for CLAG (n=97) and 23.8% for MEC (n=65) (P=0.048), with median overall survival (OS) of 7.3 and 4.5 months, respectively (P=0.05). In primary refractory disease, CR was 45.5% for CLAG and 22.2% for MEC (P=0.09), with median OS of 11 and 4.5 months, respectively (P=0.07). In first relapse, CR was 36.8% and 25.9% (P=0.35) and median OS was 6.7 and 6.7 months, respectively (P=0.87). Our data support use of CLAG for RR-AML.Entities:
Mesh：
Substances：
Year: 2010 PMID： 21109304 DOI： 10.1016/j.leukres.2010.09.002
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156